16 Mar 2018
LIBERUM: Shield Therapeutics* - Feraccru demonstrates efficacy in new analysis; Confounding events impacted failed top-line data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LIBERUM: Shield Therapeutics* - Feraccru demonstrates efficacy in new analysis; Confounding events impacted failed top-line data
Shield Therapeutics Plc (STX:LON) | 1.4 0 0.0% | Mkt Cap: 11.1m
- Published:
16 Mar 2018 -
Author:
Roger Franklin | Graham Doyle -
Pages:
3